Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00258843
Status:
COMPLETED
Last Update Posted:
2014-01-22
First Post:
2005-11-24
Brief Title:
Safety of Imovax Polio in Chinese Infants and Children
Sponsor:
Sanofi Pasteur a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
Clinical Safety Evaluation Study of the Sanofi Pasteurs Inactivated Poliomyelitis Vaccine IMOVAX Polio Administered as a Single Booster Dose at 18 Months of Age in Healthy Chinese Children and as the First Dose of Primary Vaccination at 2 Months of Age in Healthy Chinese Infants
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To describe the tolerance in terms of occurrence of serious adverse reactions and severe adverse reactions injection site and systemic within eight days after one dose of IMOVAX Polio administered in children and infants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None